Clinical Trials
12 trialsNCT01997190 2023-08-25
MpeTK01
Candel Therapeutics, Inc.
Phase 1 Completed
NCT04123886 2022-05-06
A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion
Sichuan Clover Biopharmaceuticals, Inc.
Phase 1 Completed
NCT03869697 2022-02-02
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions
Clover Biopharmaceuticals, Ltd
Phase 1 Completed
NCT01302808 2021-01-20
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT01999985 2020-11-27
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00066404 2020-05-13
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00533585 2016-02-10
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00019825 2015-04-29
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
National Cancer Institute (NCI)
Phase 1 Completed
NCT00004074 2013-02-28
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005842 2013-02-11
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00052338 2013-01-23
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00114205 2010-03-18
Surgery and Intrapleural Docetaxel in Treating Patients With Malignant Pleural Effusion
National Cancer Institute (NCI)
Phase 1 Completed